Balance Sheets (Unaudited) - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021
Current assets:
Cash and cash equivalents	$ 138,090	$ 183,259
Prepaid expenses and other current assets	7,651	3,267
Total current assets	145,741	186,526
Property, plant and equipment, net	708	650
Operating lease right-of-use assets	1,795	1,914
Other long-term assets	805	341
Total assets	149,049	189,431
Current liabilities:
Accounts payable (including related party amounts of $82 and $1,343, respectively)	2,858	5,150
Accrued clinical trial expenses		1,402
Accrued expenses (including related party amounts of $872 and $2,330, respectively)	7,565	11,405
Accrued interest	481	477
Operating lease liabilities, current	490	487
Total current liabilities	11,394	18,921
Long-term debt, net of discount	91,037	89,671
Operating lease liabilities	1,083	1,183
Other long-term liabilities	7,500	7,500
Total liabilities	111,014	117,275
Commitments and contingencies (Note 4)
Stockholders’ equity:
Preferred stock, $0.0001 par value; authorized shares - 40,000,000; no shares issued and outstanding at March 31, 2022 and December 31, 2021
Common stock, $0.0001 par value; authorized shares - 400,000,000; issued shares - 39,072,046 and 31,656,035 at March 31, 2022 and December 31, 2021, respectively; outstanding shares - 38,149,813 and 30,511,226 at March 31, 2022 and December 31, 2021, respectively	3	3
Treasury stock - 19 and 1 at March 31, 2022 and December 31, 2021, respectively
Additional paid-in capital	608,067	601,523
Accumulated deficit	(570,035)	(529,370)
Total stockholders’ equity	38,035	72,156
Total liabilities and stockholders’ equity	$ 149,049	$ 189,431